X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Facilities & Operation

Promising Excipient&Dosage Market and Rigid Social Demand for BPCs

Yuvraj_pawp by Yuvraj_pawp
22nd February 2016
in Facilities & Operation

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

CPhI China, hosted by UBM EMEA and China Chamber of Commerce of Medicines & Health Products Importers & Exporters and co-organized by UBM Sinoexpo, will be held on 21 – 23rd June 2016 in Shanghai New International Expo Center. After fifteen years of experience and accumulation, CPhI China 2016 is poised for a larger size of exhibition, more elaborate zoning division and richer conferences and activities in the corresponding period, which is bound to be a splendid, high-end and unprecedented annual event in China’s pharmaceutical industry.

Rising momentum in BPC export as always
In the first three quarters in 2015, the gross amount of import and export of western medicine slowed down, growing as little as 2.19% YoY. However, the rigid demand in export remained unchanged. Data showed that the demand for western medicine in North America, Europe, Asia and other major export markets continued increasing steadily remained and Chinese BPC export accounted for as high as 81.6%. Therefore, China has kept its position as the largest BPC supplier. Besides, the State Council had deployed policies and measures to boost foreign trade growth in July 2015, supplying a system support for the sustainable growth in China’s drug import and export. Under these circumstances, CPhI China is expected to continue to give full play to itsexport oriented advantages and build a global one-stop pharmaceutical trading platform.

Well-developedproduct zoning and potential industrial development
Located in Shanghai New International Expo Center, CPhI China 2016 is expected to cover over 200,000m2 of the area and attract over 65,000 visits from both, China and abroad.The show provides end-to-end scope experience, including pharmaceutical ingredients, pharmaceutical excipients&dosages, contracting, biotechnology, natural extracts, intermediates, industry of fine chemicals, etc. The most anticipated zone in 2016 will beExcipient &Dosage. It is well known that this product zone is popular in the pharmaceutical industry nowadays. Accounting for over 80% of a drug in its content, the quality of pharmaceutical excipient determines the risks of drug safety and plays a key role in the quality of dosages. Excipient &Dosagezone– a main push of CPhI China — has been well-established after two years of growth. So far, the zone has converged North China Pharmaceutical, Huahai Pharmaceutical, Qilu Pharmaceutical, CSPC, Hisoar Pharmaceutical, Shijiazhuang No.4 Pharmaceutical, Livzon Pharmaceutical, Sunhere Pharmaceutical, NKY Pharmaceutical, ER-KANG Pharmaceutical, Xinhua Pharmaceutical and other domestically well-known excipient and dosage makers.

Rich onsite conference program and forums covering the latest trends
A series of high-quality conferences and forums will take place during CPhI China, bringing the latest market news for exhibitors and visitors, as well as establishing the platform for mutual study, dialogue, communication and rendering perfect chances for industry peers to build abundant interpersonal links. The well-established forums, built years under CPhI China brand, including the Seventh China-World CEO Summit, CPhI, ICSE & P-MEC China Innovation & Development Forum, CPhI International Agencies Updates, etc., will focus on methods to tackle fluctuating global pharmaceutical patterns and analyze relevant problems of supervision, policy, etc. in pharmaceutical transformation and upgrading, committed to help pharmaceutical companies further enhancing their competitiveness.

Exhibiting Profile

  • General zone: pharmaceutical ingredients, antibiotics, alkaloids, amino acids, etc.
  • Excipient, formulation and dosage zone: preservatives, emulgators/ solubilizers, microcapsules, solvents, pharmaceutical chemicals, TCMs, TCM ingredients, TCM decoction pieces, OTC drugs, biopharmaceutical product, biological product, health products, etc. 
  • ICSE zone: Composite customization, pre-clinical and clinical test, technology development/optimization, customized manufacturing, etc. 
  • BioPh zone: Protein/ antigen/ polypeptide, enzyme, protein purification/ modification/ inspection/ analysis, biological preparations, vaccines, antibodies, etc. 
  • NEX zone: Plant extracts, animal extracts, health product ingredients, TCM ingredients, etc. 
  • Intermediates and fine chemical zone: Intermediates (general classification), biocatalysts, chiral intermediates, fine chemical industry (general classification), etc.


Online visitor registration is now open! Please visit http://www.cphi.com/china to register or contact Ms. Tina Zheng (tina.zheng@ubmsinoexpo.com) for more information.

Previous Post

Quality and Clean Room Microenvironment Created by Innovation: EP & Clean Tech China launches the Discovery Tour onAir Treatment

Next Post

AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds

Related Posts

Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Clinical Trials

Oracle Wins the Asia Pacific Biopharma Excellence Awards

21st March 2025
Facilities & Operation

Robust Supply Chains Are Essential For Affordable Drugs

18th May 2024
Essential Elements of Quality Management In Lab Practices
Facilities & Operation

8 Essential Elements of Quality Management In Lab Practices

18th May 2024
Facilities & Operation

FDA Solidifies Its Authority Over Laboratory-Developed Tests

18th May 2024
Facilities & Operation

100% Renewable Electricity Record Hit By Charles River Labs

17th May 2024
Next Post

AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In